Consequently, ALT has traditionally been considered an adverse prognostic marker in aggressive malignancies such as osteosarcoma, pancreatic neuroendocrine tumors, and high-grade sarcomas. The gene discussed is GPT; the disease is pancreatic neuroendocrine tumor.